Effects of CB1 receptor negative allosteric modulator Org27569 on oxycodone withdrawal symptoms in mice

DOI: https://doi.org/10.1007/s00213-024-06591-z
2024-04-28
Psychopharmacology
Abstract:Targeting cannabinoid receptor type 1 (CB1R) has shown promise for treating opioid withdrawal symptoms. This study aimed to investigate the efficacy of a specific CB1R negative allosteric modulator (NAM), Org27569, in reducing both naloxone-precipitated and protracted withdrawal symptoms in oxycodone-dependent mice.
pharmacology & pharmacy,neurosciences,psychiatry
What problem does this paper attempt to address?